MedPath

Cefoxitin

Generic Name
Cefoxitin
Drug Type
Small Molecule
Chemical Formula
C16H17N3O7S2
CAS Number
35607-66-0
Unique Ingredient Identifier
6OEV9DX57Y

Overview

Cefoxitin is a semi-synthetic, broad-spectrum cepha antibiotic for intravenous administration. It is derived from cephamycin C, which is produced by Streptomyces lactamdurans.

Indication

For the treatment of serious infections caused by susceptible strains microorganisms.

Associated Conditions

  • Abscess, Intra-Abdominal
  • Animal bite
  • Bacterial Infections
  • Bacterial Urinary Tract Infections
  • Bone and Joint Infections
  • Endometritis
  • Flu caused by Influenza
  • Gynecological Infection
  • Intraabdominal Infections
  • Lower respiratory tract infection bacterial
  • Lung Abscess
  • Pelvic Inflammatory Disease (PID)
  • Pelvic cellulitis
  • Peritonitis
  • Pneumonia
  • Septicemia
  • Skin and Subcutaneous Tissue Bacterial Infections

Research Report

Published: Jun 4, 2025

Cefoxitin: A Comprehensive Pharmacological and Clinical Review

1. Introduction to Cefoxitin

1.1. Overview, Classification, and Origin

Cefoxitin is a semi-synthetic, broad-spectrum antibiotic agent intended for parenteral administration, primarily utilized in the management of serious bacterial infections.[1] Within the landscape of antimicrobial agents, Cefoxitin holds a distinct position. It is classified as a cephamycin antibiotic, a subgroup of beta-lactam antibiotics, and is frequently categorized alongside second-generation cephalosporins.[1] This dual classification is not merely academic; it reflects its unique structural attributes and, consequently, its particular spectrum of activity and clinical utility. The "second-generation cephalosporin" grouping generally implies an enhanced spectrum against Gram-negative bacteria compared to first-generation agents, often with some activity against anaerobic bacteria. Cefoxitin aligns with this but its cephamycin nature, specifically the presence of a 7-alpha-methoxy group on its core structure, confers a notable degree of stability against a wide array of bacterial beta-lactamases.[2] This enzymatic stability is a cornerstone of its efficacy against certain challenging pathogens, including many anaerobic organisms, and distinguishes it from many other cephalosporins.

Continue reading the full research report

Clinical Trials

Title
Posted
Study ID
Phase
Status
Sponsor
2025/03/06
Phase 1
Active, not recruiting
2024/08/20
Phase 3
Recruiting
2020/03/17
Phase 2
Recruiting
2017/09/01
Phase 3
Completed
2016/12/07
Not Applicable
UNKNOWN
Hospital de Santa Maria, Portugal
2016/03/09
Phase 4
Completed
2015/06/18
Phase 4
Terminated
Central Hospital, Nancy, France
2013/03/29
Not Applicable
Terminated

FDA Drug Approvals

Approved Product
Manufacturer
NDC Code
Route
Strength
Effective Date
No FDA approvals found for this drug.

EMA Drug Approvals

Approved Product
Authorization Holder
Status
Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

Approved Product
Manufacturer
Approval Number
Dosage Form
Strength
Approval Date
No HSA approvals found for this drug.

NMPA Drug Approvals

Approved Product
Company
Approval Number
Drug Type
Dosage Form
Approval Date
No NMPA approvals found for this drug.

PPB Drug Approvals

Approved Product
Registration No.
Company
Licence No.
Strength
Registration Date
No PPB approvals found for this drug.

TGA Drug Approvals

Approved Product
ARTG ID
Sponsor
Registration Type
Status
Registration Date
No TGA approvals found for this drug.

Health Canada Drug Approvals

Approved Product
Company
DIN
Dosage Form
Strength
Market Date
No Health Canada approvals found for this drug.

CIMA AEMPS Drug Approvals

Approved Product
Company
Registration Number
Pharmaceutical Form
Prescription Type
Status
No CIMA AEMPS (Spain) approvals found for this drug.

Philippines FDA Drug Approvals

Approved Product
Company
License Number
Dosage Form
Strength
Approval Date
No Philippines FDA approvals found for this drug.

Saudi SFDA Drug Approvals

Approved Product
Company
License Number
Dosage Form
Strength
Approval Date
No Saudi SFDA approvals found for this drug.

Malaysia NPRA Drug Approvals

Approved Product
Company
Registration Number
Dosage Form
Strength
Approval Date
No Malaysia NPRA approvals found for this drug.

UK EMC Drug Information

Medicine Name
MA Holder
MA Number
Pharmaceutical Form
Active Ingredient
Authorization Date
No UK EMC drug information found for this drug.

Help Us Improve

Your feedback helps us provide better drug information and insights.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.